Claire A. Leckey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Claire A. Leckey has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Selina Wray
UCL Queen Square Institute of Neurology
3 shared publications - Charles Arber
Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
2 shared publications - Henrik Zetterberg
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden
2 shared publications - Ross W. Paterson
Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK
2 shared publications - Argyro Alatza
Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
1 shared publication - Christopher R. S. Belder
School of Medicine, Adelaide University, Adelaide, South Australia, Australia
1 shared publication
Latest Publications
- Open Access
Unbiased data-driven analysis of five amyloid-beta peptides for biomarker investigations in familial Alzheimer’s disease
Structured INTRODUCTION: Changes to the relative abundance of amyloid-beta (Aβ) peptides are hallmarks of Alzheimer’s disease (AD). iPSC-derived neurons offer a physiological model of Aβ production. We employed unbiased, data-driven analyses to investigate combinations of Aβ peptides as AD biomarkers and the relative contribution of peptides to AD pathogenesis. METHODS: We measured Aβ37, Aβ38, Aβ40, Aβ42 and Aβ43 in ten iPSC-neuronal cultures from PSEN1 mutation carriers. We combined these data with published cell model data and used linear weighted combinations to 1) distinguish AD from controls, and 2) predict age-at-onset for PSEN1 mutations. RESULTS: Data-driven approaches distinguished Aβ42 and Aβ43 from shorter peptides, providing unbiased evidence for their contribution to disease. Weighted linear combinations of Aβ peptides outperform Aβ42/40 and provide insights into relative peptide contribution as biomarkers; the optimal ratio for all data is represented as (21 · Aβ37 + 10 · Aβ38 + 69 · Aβ40)/(94 · Aβ42 + 6 · Aβ43). DISCUSSION: The algorithm discovered herein can be further refined to improve biomarkers for AD.
Open AccessUnbiased data-driven analysis of five amyloid-beta peptides for biomarker investigations in familial Alzheimer’s disease
Structured INTRODUCTION: Changes to the relative abundance of amyloid-beta (Aβ) peptides are hallmarks of Alzheimer’s disease (AD). iPSC-derived neurons offer a physiological model of Aβ production. We employed unbiased, data-driven analyses to investigate combinations of Aβ peptides as AD biomarkers and the relative contribution of peptides to AD pathogenesis. METHODS: We measured Aβ37, Aβ38, Aβ40, Aβ42 and Aβ43 in ten iPSC-neuronal cultures from PSEN1 mutation carriers. We combined these data with published cell model data and used linear weighted combinations to 1) distinguish AD from controls, and 2) predict age-at-onset for PSEN1 mutations. RESULTS: Data-driven approaches distinguished Aβ42 and Aβ43 from shorter peptides, providing unbiased evidence for their contribution to disease. Weighted linear combinations of Aβ peptides outperform Aβ42/40 and provide insights into relative peptide contribution as biomarkers; the optimal ratio for all data is represented as (21 · Aβ37 + 10 · Aβ38 + 69 · Aβ40)/(94 · Aβ42 + 6 · Aβ43). DISCUSSION: The algorithm discovered herein can be further refined to improve biomarkers for AD.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Stable Isotope Labelling Kinetics tracing of Neurofilament Light in stem cell‐derived neurons and humans
Background: Neurofilament light (NfL) is a neuronal cytoskeletal protein that is released into the extracellular environment from degenerated axons. As such, NfL levels in cerebrospinal fluid (CSF) and serum have been proposed as a promising biomarker of neurodegeneration, yet the metabolism of NfL in human neurons is unknown. Kinetic protein labelling can provide protein half‐lives and rates of production and clearance in vitro and in vivo.Method: Using a stable isotope tracer (13C6‐leucine), we labelled two lines of pluripotent stem cell‐derived neurons and human study participants with primary tauopathies (n = 9). We collected neuronal lysates and conditioned media every three days during the labelling (“pulse”) and post‐labelling (“chase”) phases. CSF samples were collected across five visits, scheduled around 4, 14, 20, 60 and 120 days post‐labelling. We measured the ratio of labelled to unlabelled NfL using targeted mass spectrometry workflows to quantitate the rates of protein labelling (fractional synthesis rate) and label loss (fractional clearance rate), together providing the protein turnover rate.Result: The average half‐life of NfL in cell lysates was four days (± 1.06 SD, n = 3 independent biological replicates). The turnover of extracellular NfL in neuronal conditioned media was slower than that found in neuronal lysates, suggesting that NfL is a rather stable protein in the extracellular milieu in vitro. In contrast, analysis of CSF from the in vivo tauopathy cohort detected low labelling of NfL (0.04 – 0.36%) by 120 days (n = 5), indicating that in vivo turnover is exceptionally slower than in vitro and that extended CSF collection and analysis >120 days post‐labelling is crucial to capture NfL production and clearance in vivo. To this end, additional analysis of healthy controls and patients with Alzheimer’s disease (control and AD cohorts; n = 24), which include CSF collection up to 219 ‐ 444 days post‐labelling, is ongoing.Conclusion: Tracking of both intracellular and extracellular NfL in neurons derived from healthy control individuals, as well as cells with mutations implicated in neurodegenerative diseases, are expected to shed light into the dynamics of NfL turnover in both physiological and pathological conditions. This will be critical for interpreting NfL in response to disease‐modifying therapies.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Open AccessStable Isotope Labelling Kinetics tracing of Neurofilament Light in stem cell‐derived neurons and humans
Background: Neurofilament light (NfL) is a neuronal cytoskeletal protein that is released into the extracellular environment from degenerated axons. As such, NfL levels in cerebrospinal fluid (CSF) and serum have been proposed as a promising biomarker of neurodegeneration, yet the metabolism of NfL in human neurons is unknown. Kinetic protein labelling can provide protein half‐lives and rates of production and clearance in vitro and in vivo.Method: Using a stable isotope tracer (13C6‐leucine), we labelled two lines of pluripotent stem cell‐derived neurons and human study participants with primary tauopathies (n = 9). We collected neuronal lysates and conditioned media every three days during the labelling (“pulse”) and post‐labelling (“chase”) phases. CSF samples were collected across five visits, scheduled around 4, 14, 20, 60 and 120 days post‐labelling. We measured the ratio of labelled to unlabelled NfL using targeted mass spectrometry workflows to quantitate the rates of protein labelling (fractional synthesis rate) and label loss (fractional clearance rate), together providing the protein turnover rate.Result: The average half‐life of NfL in cell lysates was four days (± 1.06 SD, n = 3 independent biological replicates). The turnover of extracellular NfL in neuronal conditioned media was slower than that found in neuronal lysates, suggesting that NfL is a rather stable protein in the extracellular milieu in vitro. In contrast, analysis of CSF from the in vivo tauopathy cohort detected low labelling of NfL (0.04 – 0.36%) by 120 days (n = 5), indicating that in vivo turnover is exceptionally slower than in vitro and that extended CSF collection and analysis >120 days post‐labelling is crucial to capture NfL production and clearance in vivo. To this end, additional analysis of healthy controls and patients with Alzheimer’s disease (control and AD cohorts; n = 24), which include CSF collection up to 219 ‐ 444 days post‐labelling, is ongoing.Conclusion: Tracking of both intracellular and extracellular NfL in neurons derived from healthy control individuals, as well as cells with mutations implicated in neurodegenerative diseases, are expected to shed light into the dynamics of NfL turnover in both physiological and pathological conditions. This will be critical for interpreting NfL in response to disease‐modifying therapies.
- Open Access
- 4 February 2021
- Published by Wiley in Journal of Neurochemistry
- Vol. 159 (2) , 305-317
Mass spectrometry analysis of tau and amyloid‐beta in iPSC‐derived models of Alzheimer’s disease and dementia
Induced pluripotent stem cell (iPSC) technology enables the generation of human neurons in vitro, which contain the precise genome of the cell donor, therefore permitting the generation of disease models from individuals with a disease‐associated genotype of interest. This approach has been extensively used to model inherited forms of Alzheimer’s disease and frontotemporal dementia. The combination of iPSC‐derived neuronal models with targeted mass spectrometry analysis has provided unprecedented insights into the regulation of specific proteins in human neuronal physiology and pathology. For example, enabling investigations into tau and APP/Aβ, specifically: protein isoform expression, relative levels of cleavage fragments, aggregated species and functionally critical post‐translational modifications. The use of mass spectrometry has enabled a determination of how closely iPSC‐derived models recapitulate disease profiles observed in the human brain. This review will highlight the progress to date in studies using iPSCs and mass spectrometry to model Alzheimer’s disease and dementia. We go on to convey our optimism, as studies in the near future will make use of this precedent, together with novel techniques such as genome editing and stable isotope labelling, to provide real progress towards an in depth understanding of early neurodegenerative processes and development of novel therapeutic agents.
- 4 February 2021
- Published by Wiley in Journal of Neurochemistry
- Vol. 159 (2) , 305-317
Open AccessMass spectrometry analysis of tau and amyloid‐beta in iPSC‐derived models of Alzheimer’s disease and dementia
Induced pluripotent stem cell (iPSC) technology enables the generation of human neurons in vitro, which contain the precise genome of the cell donor, therefore permitting the generation of disease models from individuals with a disease‐associated genotype of interest. This approach has been extensively used to model inherited forms of Alzheimer’s disease and frontotemporal dementia. The combination of iPSC‐derived neuronal models with targeted mass spectrometry analysis has provided unprecedented insights into the regulation of specific proteins in human neuronal physiology and pathology. For example, enabling investigations into tau and APP/Aβ, specifically: protein isoform expression, relative levels of cleavage fragments, aggregated species and functionally critical post‐translational modifications. The use of mass spectrometry has enabled a determination of how closely iPSC‐derived models recapitulate disease profiles observed in the human brain. This review will highlight the progress to date in studies using iPSCs and mass spectrometry to model Alzheimer’s disease and dementia. We go on to convey our optimism, as studies in the near future will make use of this precedent, together with novel techniques such as genome editing and stable isotope labelling, to provide real progress towards an in depth understanding of early neurodegenerative processes and development of novel therapeutic agents.